Pulmonary Embolism - Pipeline Review, H2 2016

Date: August 17, 2016
Pages: 51
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P760D893689EN
Leaflet:

Download PDF Leaflet

Pulmonary Embolism - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Pulmonary Embolism - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Embolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism
  • The report reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Embolism therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Embolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Embolism
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Pulmonary Embolism Overview
Therapeutics Development
Pipeline Products for Pulmonary Embolism - Overview
Pipeline Products for Pulmonary Embolism - Comparative Analysis
Pulmonary Embolism - Therapeutics under Development by Companies
Pulmonary Embolism - Therapeutics under Investigation by Universities/Institutes
Pulmonary Embolism - Pipeline Products Glance
Late Stage Products
Early Stage Products
Pulmonary Embolism - Products under Development by Companies
Pulmonary Embolism - Products under Investigation by Universities/Institutes
Pulmonary Embolism - Companies Involved in Therapeutics Development
Accu-Break Pharmaceuticals, Inc.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Pulmonary Embolism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-023725 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenecteplase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
warfarin potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmonary Embolism - Dormant Projects
Pulmonary Embolism - Discontinued Products
Pulmonary Embolism - Product Development Milestones
Featured News & Press Releases
Apr 25, 2016: Patent Term for Rivaroxaban Extended in US
Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials
Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy
Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism
Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE
Dec 03, 2013: New Data to be Presented on Bayer’s Xarelto Single-Drug Solution for the Treatment and Prevention of Recurrent Pulmonary Embolism and Deep Vein Thrombosis
Sep 20, 2013: Pooled Analysis Confirms XARELTO has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Pulmonary Embolism, H2 2016
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals, Inc., H2 2016
Pulmonary Embolism - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pulmonary Embolism - Pipeline by Genentech, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pulmonary Embolism - Dormant Projects, H2 2016
Pulmonary Embolism - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Pulmonary Embolism, H2 2016
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Pulmonary Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 377 pages

Ask Your Question

Pulmonary Embolism - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: